Elevated InsP3R expression underlies enhanced calcium fluxes and spontaneous extra-systolic calcium release events in hypertrophic cardiac myocytes

How to cite:

Harzheim, Dagmar; Talasila, Amarnath; Movassagh, Mehregan; Foo, Roger S-Y.; Figg, Nichola; Bootman, Martin D. and Roderick, H. Llewelyn (2010). Elevated InsP3R expression underlies enhanced calcium fluxes and spontaneous extra-systolic calcium release events in hypertrophic cardiac myocytes. Channels (Austin), 4(1) pp. 67–71.

For guidance on citations see FAQs.

© 2010 Landes Bioscience

Version: Version of Record

Link(s) to article on publisher’s website:
http://dx.doi.org/doi:10.4161/chan.4.1.10531

Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies page.
Elevated InsP$_3$R expression underlies enhanced calcium fluxes and spontaneous extra-systolic calcium release events in hypertrophic cardiac myocytes

Dagmar Harzheim,1,† Amarnath Talasila,1 Mehregan Movassagh,2 Roger S.-Y. Foo,2 Nichola Figg,2 Martin D. Bootman1 and H. Llewelyn Roderick1,3,*

1Department of Molecular Signaling; Babraham Institute; Cambridge, UK; 2Addenbrooke’s Centre for Clinical Investigation; Cambridge, UK; 3Department of Pharmacology; University of Cambridge; Cambridge, UK

†Current Address: Caesar Research Center; Bonn, Germany

Cardiac hypertrophy is associated with profound remodeling of Ca$^{2+}$-signaling pathways. During the early, compensated stages of hypertrophy, Ca$^{2+}$ fluxes may be enhanced to facilitate greater contraction, whereas as the hypertrophied heart decompensates, Ca$^{2+}$ homeostatic mechanisms are dysregulated leading to decreased contractility, arrhythmia and death. Although ryanodine receptor Ca$^{2+}$ release channels (RyR) on the sarcoplasmic reticulum (SR) intracellular Ca$^{2+}$ store are primarily responsible for the Ca$^{2+}$ flux that induces myocyte contraction, a role for Ca$^{2+}$ release via the inositol 1,4,5-trisphosphate receptor (InsP$_3$R) in cardiac physiology has also emerged. Specifically, InsP$_3$-induced Ca$^{2+}$ signals generated following myocyte stimulation with an InsP$_3$-generating agonist (e.g., endothelin, ET-1), lead to modulation of Ca$^{2+}$ signals associated with excitation-contraction coupling (ECC) and the induction of spontaneous Ca$^{2+}$ release events that cause cellular arrhythmia. Using myocytes from spontaneously hypertensive rats (SHR), we recently reported that expression of the type 2 InsP$_3$R (InsP$_3$R2) is significantly increased during hypertrophy. Notably, this increased expression was restricted to the junctional SR in close proximity to RyRs. There, enhanced Ca$^{2+}$ release via InsP$_3$Rs serves to sensitize neighboring RyRs causing an augmentation of Ca$^{2+}$ fluxes during ECC as well as an increase in non-triggered Ca$^{2+}$ release events.

Although the sensitization of RyRs may be a beneficial consequence of elevated InsP$_3$R expression during hypertrophy, the spontaneous Ca$^{2+}$ release events are potentially of pathological significance giving rise to cardiac arrhythmia. InsP$_3$R2 expression was also increased in hypertrophic hearts from patients with ischemic dilated cardiomyopathy and aortically-banded mice demonstrating that increased InsP$_3$R expression may be a general phenomenon that underlies Ca$^{2+}$ changes during hypertrophy.

To meet increased haemodynamic requirements, or as a result of damage, the heart elicits a hypertrophic response. This response is characterized by an enlargement of the cardiac muscle mass due to increased cell size rather than cell number.1,2 Hypertrophy results from both physiological (pregnancy, exercise) and pathological stimuli (hypertension, ischemic heart disease) and can initially be a beneficial adaptive response. However, persistent cardiac stress may lead to a decompensated form of hypertrophy, which can lead to arrhythmia and ultimately heart failure and death. Indeed, cardiac hypertrophy is a predictor of future heart failure and death.2,3 These pathologies are of major clinical significance and together with other cardiovascular diseases are now the primary cause of death in the developed world.4

Ca$^{2+}$ is key to cardiac function—stimulating myocyte contraction via

Key words: IP$_3$, IP$_3$R, calcium, hypertrophy, cardiac, arrhythmia, hypertension.

Submitted: 10/17/09
Accepted: 10/17/09
Previously published online: www.landesbioscience.com/journals/channels/article/10531

© 2010 Landes Bioscience
excitation-contraction coupling (ECC) and controlling the transcription of genes that underlies the induction of hypertrophy. ECC is initiated by an action potential (AP) originating at the sinoatrial node. Coordinated conduction of this action potential through the heart results in a synchronized contraction of the heart chambers. The propagating action potential depolarizes the myocyte plasma membrane thereby opening voltage-sensitive L-type Ca²⁺ channels and allowing Ca²⁺ to enter the cell. This ‘trigger’ Ca²⁺, termed a sparklet, induces opening of ryanodine receptor (RyR) Ca²⁺ release channels on the juxtaposed sarcoplasmic reticulum (SR) intracellular Ca²⁺ store—a process called Ca²⁺-induced Ca²⁺ release (CICR). CICR causes a global elevation in Ca²⁺, which leads to myocyte contraction. Relaxation is then brought about by extrusion of Ca²⁺ across the sarcolemma by the Na⁺/Ca²⁺ exchanger (NCX) and by its sequestration into the SR by the SERCA2Ca²⁺-ATPase.

In addition to RyRs, cardiomyocytes also express inositol 1,4,5-triphosphate receptor Ca²⁺ release channels (InsP₃Rs), albeit outnumbered by RyRs 50:1. Since InsP₃Rs have been discovered in the heart, it has been questioned how the relatively small amount of Ca²⁺ that is released via InsP₃Rs can have any physiological function in the midst of the large amount of Ca²⁺ that is cycled through RyRs during every heart beat. In mammals, there are three InsP₃R isoforms (types 1, 2 and 3), with type 2 being the main isoform in the heart. InsP₃Rs have been shown to mediate inotropy and arrhythmogenmic Ca²⁺ release events as well as contribute to the hypertrophic effect of G₁-coupled agonists such as the vasoactive peptide endothelin-1 (ET-1). Profound remodeling of the Ca²⁺ signaling apparatus has been reported to occur as a result of cardiac hypertrophy and failure. Whilst enhancement of Ca²⁺ transients facilitates greater myocyte contraction during adaptive hypertrophy, Ca²⁺ fluxes are diminished during heart failure resulting in decreased contractility and thus, cardiac output. Remodeling of the activity and function of the Ca²⁺ signaling proteome also underlies the increased arrhythmias associated with hypertrophy and heart failure. Whether altered InsP₃R signaling also contributes to remodeling of Ca²⁺ homeostasis during cardiac hypertrophy is not yet determined.

In a recent study, we established that augmented expression and Ca²⁺ release through InsP₃Rs contribute to enhanced Ca²⁺ fluxes and increased spontaneous arrhythmogenic Ca²⁺ events associated with hypertrophy. As a model to study hypertrophy-dependent changes in Ca²⁺ signaling, we used hypertrophic ventricular cardiomyocytes from spontaneously hypertensive rats (SHR) and non-hypertrophic ventricular cardiomyocytes from Wistar Kyoto rats (WKY) as controls. We found that in hypertrophic myocytes InsP₃R2 expression was specifically increased in the junctional SR membrane, thereby increasing the numbers of InsP₃Rs in close proximity with type 2 RyRs (RyR2), the expression of which was unchanged as a result of hypertrophy. Enhanced Ca²⁺ release through these InsP₃Rs sensitized their neighboring RyRs, thereby enhancing CICR leading to bigger Ca²⁺ transients and greater myocyte contraction. Moreover, the sensitization of RyR opening through increased InsP₃-induced Ca²⁺ release (IICR) resulted in a higher propensity for the generation of elementary Ca²⁺ release events and extrasytolic Ca²⁺ transients, which could act as a substrate for cardiac arrhythmia in vivo. Interestingly, we could not only show that InsP₃R2 expression was increased in hypertrophic rat cardiomyocytes but also in cardiomyocytes isolated from aortically-banded mice and in human hearts displaying ischemic dilated cardiomyopathy. We showed by immunoblotting and, as presented here, by immunohistochemistry that InsP₃R2 expression is increased in diseased human hearts compared to control hearts. These micrographs also illustrate that InsP₃R2 expression is restricted to myocytes and is not present in non-myocyte cells, for example surounding the vessels.

An increase in InsP₃R2 expression therefore seems to be a general phenomenon occurring during cardiac disease. This is surprising considering the lack of consensus regarding the different effects of hypertrophy on Ca²⁺ signaling. Although amplification of Ca²⁺ cycling is considered as a general mechanism for increasing cardiac output during hypertrophy, myocytes isolated from certain hypertrophy models exhibit either no change, or even suppression, in their ECC-mediated Ca²⁺ fluxes. As such, the mechanisms underlying remodeling of Ca²⁺ cycling during hypertrophy are not fully understood. In hypertrophic failing myocytes, Ca²⁺ cycling is suppressed causing decreased contractility. In this condition, defects in coupling between L-type channels and RyRs due to a breakdown in the t-tubular network, decreases in SERCA-mediated Ca²⁺ sequestration into the SR lumen, and increased Ca²⁺ leak from the SR via hyper-phosphorylated RyRs have all been shown to be involved in pathology.

The reason for this array of Ca²⁺ signaling phenotypes during hypertrophy may lie in the panoply of hypertrophy models employed. For example, hypertrophy is induced by haemodynamic loading (such as aortic banding), interruption of myocardial blood supply (infarction) and interfering of heart rate (pacing or AV block). More recently, genetic models of hypertrophy have also been employed. Even more variability between studies is introduced by the hypertrophic stage at which Ca²⁺ signaling measurements are made and the location of the myoccardium from which myocytes are isolated. The SHR model offers considerable advantages. The temporal development of hypertrophy in SHR has been well characterized and develops slowly between the age of 2 and 6 months subsequent to the onset of systemic hypertension. After the development of hypertrophy, there is also a long latency before the development of heart failure at 20–24 months. This contrasts with surgically-induced models where hypertrophy develops 1–2 weeks post surgery. However, our results show that the increase in InsP₃R expression seems to be independent of how hypertrophy has been induced.

Considering the pro-arrhythmic effect of increased InsP₃R expression, which is clearly evident in our study, this raises the question of why InsP₃R expression is enhanced in hypertrophic and failing cardiomyocytes? During hypertrophy a decrease in the coupling efficiency
between plasma membrane L-type channels and RyR channels due to an increase in the width of the dyadic cleft has been observed. This deficit in ECC did not significantly affect contractile function and was overcome by beta-adrenergic stimulation. Here, sensitization of RyR opening due to increased Ca^{2+} release through InsP_{3}R_{s} could compensate for the lack of coupling efficiency, even under basal conditions.

What remains to be determined is how InsP_{3}R_{2} expression during hypertrophy is regulated and how the striking junctional pattern of InsP_{3}R_{2} expression is achieved. Our data would suggest that InsP_{3}R expression increases concomitant with or is a product of hypertrophy and is not causal. In support of this conclusion, non-hypertrophic hearts from four month old SHRs do not exhibit increased InsP_{3}R expression compared to WKY controls. Moreover, hypertrophy is induced in vitro in an InsP_{3}-dependent manner within 24 hours, a time period that would not allow for elevated InsP_{3}R expression to have effect. Thus, it is likely that the role of increased InsP_{3}R_{s} detected during hypertrophy is to modify calcium signals, and possibly also act to sustain the hypertrophic phenotype. The subcellular localization of InsP_{3}R_{2} expression could be mediated via interactions with accessory proteins such as Ankyrin B, which has been shown to localize InsP_{3}Rs. Whether the mechanisms that mediate a preferential increase in InsP_{3}R_{s} in the junctional zones and not around the nucleus during hypertrophy play any role in restricting the recently described pro-hypertrophic action of InsP_{3}-induced calcium release (IICR) in the nucleus also remains to be determined.

A dramatic consequence of hypertrophy for Ca^{2+} signaling observed in our

---

**Figure 1.** Expression of InsP_{3}R_{2} is increased in cardiomyocytes from human patients suffering from ischemic dilated cardiomyopathy. Immunohistochemical detection of InsP_{3}R_{2} (brown) in cardiomyocytes from control patients (A) and in cardiomyocytes from patients showing ischemic dilated cardiomyopathy (B). Higher magnification images for (A and B) are presented in (C and D) respectively. Control staining of hypertrophic myocytes without using InsP_{3}R_{2} primary antibody are presented at low and high magnification in (E and F) respectively. These data are representative of images taken from slides prepared from two control and two diseased hearts. Non-myocyte cells surrounding a blood vessel (indicated by the black arrow) do not stain for InsP_{3}R_{2}. The size of the bar is indicated in each image. The nuclei are indicated in blue.
study was the increased occurrence of extra-systolic Ca\(^{2+}\) transients following ET-1 or InsP\(_3\) ester (cell permeant InsP\(_3\)) application. The relatively low incidence of InsP\(_3\)-stimulated Ca\(^{2+}\) release events in WKY myocytes is consistent with our previous work in Wistar rat ventricular myocytes.\(^{10,20,22}\) The enhanced incidence of extra-systolic Ca\(^{2+}\) transients in hypertrophic ventricular myocytes is reminiscent of previous findings in atrial myocytes, which express ~6-fold more InsP\(_3\)Rs under normal conditions.\(^{17,20,22,36}\) Due to their higher basal expression of InsP\(_3\)Rs, stimulation of atrial myocytes with InsP\(_3\) or InsP\(_3\)R-stimulating agonists, such as ET-1, potently induce extra-systolic Ca\(^{2+}\) release events.\(^{20}\) Although insignificant by themselves, these miniature Ca\(^{2+}\) release events can provide sufficient Ca\(^{2+}\) to catalyze further Ca\(^{2+}\) release through CICR and cause AP-independent increases in [Ca\(^{2+}\)]\_i, which could potentially result in arrhythmia.\(^{17}\) This role of Ca\(^{2+}\) release through InsP\(_3\)Rs has been substantiated in InsP\(_3\)R-deficient mice, in which ET-1- and InsP\(_3\)-stimulated arrhythmias in atrial myocytes were completely abolished.\(^{17}\) Interestingly, InsP\(_3\)Rs in atrial myocytes are located on the SR underlying the sarcolemma—the functional equivalent of the junctional zone created by the juxtaposition of the SR terminal cisternae and the t-tubular membrane in ventricular myocytes.\(^{37}\) Thus, in hypertrophic ventricular myocytes, ECC may mirror that observed in atrial myocytes.

![Figure 2](image.png)

**Figure 2.** Expression of ET\(_A\)R is increased in hypertrophic SHR hypertrophic myocytes. 25 μg of total cell lysate prepared from left ventricle taken from SHR and WKY hearts from 6 month old animals was subjected to immunoblot analysis following SDS-PAGE. Analysis of samples prepared from 4 control (WKY) and 4 hypertrophic (SHR) hearts are shown. An immunoblot of α-actinin in the same samples is presented as loading control. We have previously established that myocytes from 6 month old SHRs are hypertrophic exhibiting increased size and expression of atrial natriuretic factor (ANF).\(^{15}\)

As well as being manifest as spontaneous Ca\(^{2+}\) release events and extra systolic Ca\(^{2+}\) transients, increased InsP\(_3\)R expression resulted in a greater rise in diastolic [Ca\(^{2+}\)]\_i in hypertrophic myocytes following ET-1 or IICR stimulation.\(^{15}\) As a result, diastolic [Ca\(^{2+}\)]\_i was brought closer to the threshold for activation of RyRs, thereby increasing the incidence of stochastic Ca\(^{2+}\) release events and accelerating the generation of pacing-evoked Ca\(^{2+}\) transients. These findings are consistent with data from InsP\(_3\)R2-deficient atrial myocytes which exhibited a decrease in the ET-1-evoked elevation in diastolic [Ca\(^{2+}\)]\_i.\(^{17}\)

The arrhythmogenic effect of InsP\(_3\)-stimulated Ca\(^{2+}\) release events in the ventricles is potentially more catastrophic than in the atria. Whereas atrial fibrillation only has potentially serious consequences over the long term, ventricular fibrillation is potentially immediately life-threatening. This situation is further exacerbated by increases in the expression of additional components of the pathway that leads to InsP\(_3\) generation. Specifically, levels of cardiac ET-1 and also that of its receptor (ET\(_A\)R), are elevated during development of hypertension and hypothyroidism (Fig. 2).\(^{38,39}\) Moreover, phosphoprotein C beta1 levels have also been recently reported to be increased during atrial hypothyroidism.\(^{40}\) Together, enhanced activity of this signaling pathway as a result of hypertrophy would promote greater Ca\(^{2+}\) release through InsP\(_3\)Rs, and heighten the susceptibility for arrhythmias, even under non-stressed conditions.

Our recent study\(^{15}\) presents a plausible mechanism why hypertrophic hearts are more prone to cardiac arrhythmia and proposes InsP\(_3\)R2 as a possible target for the development of new drugs against hypertrophy-related arrhythmia.

**Materials and Methods**

**Animal models.** Male SHRs and normotensive Wistar-Kyoto (WKY) rats were obtained from Harlan, UK, and were housed under control conditions with ad libitum food and water. All experiments were performed in accordance with the guidelines from the code of practice for humane killing under Schedule 1 of the Animals (Scientific Procedures) Act 1986.

**Patients.** Left ventricular tissue samples of human failing hearts were from individuals undergoing heart transplantation due to end-stage heart failure. All samples were obtained from male caucassians, aged 41–62. Samples from non-failing donor hearts were provided by the “UK Human Tissue Bank.” After cardiectomy, left ventricular samples were frozen in liquid nitrogen and stored at -80°C. Detailed information about the patients is included in Harzheim et al. 2009. All experiments involving human tissue samples have been approved by the Cambridgeshire Research Ethics Committee.

**Immunohistochemistry.** Immunohistochemistry was performed as previously described.\(^{41}\) Paraffin tissue sections were prepared from non-diseased human hearts and from hearts with ischemic dilated cardiomyopathy (tissue source described above). Sections were deparaffinized and antigen retrieved using basic citrate buffer, after which slides were washed with PBS and blocked with 0.3% H\(_2\)O\(_2\)/PBS for 10 mins. After a further wash in PBS, slides were incubated with 5% BSA/PBS for 1 hour at room temp. Slides were then incubated overnight at 4°C with monoclonal rat anti InsP\(_3\)R2 antibody\(^{15}\) diluted at 1:50 in 5% BSA. After removal of excess primary antibody by washing in PBS, slides were incubated with HRP-conjugated secondary antibody diluted at 1:4000 for 30 minutes at room temp. After washing, slides were incubated with ABC reagent for 30 mins at...
room temp after which they were washed, visualized with DAB, counterstained with Harris' haematoxylin and mounted.

**Immunoblot detection of ET<sub>A</sub>R.** Protein expression was detected as previously described. In brief, proteins were extracted from ventricular myocytes from WKY rats and SHR's in lysis buffer (10 mM Tris-HCl, pH 7.6, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, protease and phosphatase inhibitor cocktail (Sigma)). Protein extracts (25 μg) were then subjected to SDS-PAGE (10% Bis-Tris NuPage, Invitrogen) and subsequent immunoblot analysis with antibodies directed against the ET<sub>A</sub>R (Alomone labs) and alpha-actinin (Sigma). Immunocomplexes were detected by enhanced chemiluminescence with anti-mouse or anti-rabbit IgG coupled to horseradish peroxidase as the secondary antibody (Jackson Immuno Research Laboratories).

**Acknowledgements**

The work was supported by The BHF (PG/06/034/20637 and PG/07/040) and the BBSRC. H.L.R. is a Royal Society Wolfson College for a JR Fellowship.

**References**

1. Dorn GW, 2nd, Molkentin JD. Manipulating cardiac contractility in heart failure: data from mice and men. Circulation 2004; 109:20-2.
2. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection and prognosis. Circulation 2000; 102:470-9.
3. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. American Heart Journal 2001; 141:334-41.
4. Allender S, Peto V, Scarborough P, Boxer A, Raynor M. Coronary Heart Disease Statistics. BHF, London 2006.
5. Bers DM. Cardiac excitation-contraction coupling. Nature 2002; 415:198-205.
6. Frey N, McKinsey TA, Olson EN. Decoding calcium signals involved in cardiac growth and function. Nat Med 2000; 6:1221-7.
7. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signaling pathways. Nat Rev Mol Cell Biol 2006; 7:589-600.
8. Wang SQ, Song LS, Lakatta EG, Cheng H. Ca<sup>2+</sup> signaling between single L-type Ca<sup>2+</sup> channels and ryanodine receptors in heart cells. Nature 2001; 410:592-6.
9. Rodenrick BH, Berridge MJ, Bootman MD. Calcium-induced calcium release. Curr Biol 2003; 13:425.
10. Lipp P, Laine M, Tovey SC, Burrell KM, Berridge MJ, Li W, Bootman MD. Functional InsP<sub>3</sub> receptors that may modulate excitation-contraction coupling in the heart. Curr Biol 2000; 10:399-42.
11. Moschella MC, Marks AR. Inositol 1,4,5-trisphosphate receptor expression in cardiac myocytes. J Cell Biol 1993; 120:1137-46.
12. Perez PJ, Ramos-Franco J, Fill M, Mignery GA. Identification and functional reconstitution of the type-2 inositol 1,4,5-trisphosphate receptor from ventricular cardiac myocytes. J Biol Chem 1997; 272:23960-9.
13. Foskett JK, White C, Cheung KH, Mak DO. Inositol trisphosphate receptor Ca<sup>2+</sup> release channels. Physiol Rev 2007; 87:593-658.
14. Patel S, Joseph SK, Thomas AP. Molecular properties of inositol 1,4,5-trisphosphate receptors. Cell Calcium 1999; 25:247-64.
15. Harzem D, Movassagh M, Foo RS, Ritter O, Tashfeen A, Conway SJ, et al. Increased InsP<sub>3</sub>Rs in the functional sarcoplasmic reticulum augment Ca<sup>2+</sup> transients and arrhythmias associated with cardiac hypertrophy. Proc Natl Acad Sci USA 2009; 106:11406-11.
16. Higazi DR, Fearnley CJ, Drawell FM, Talasala A, Coops EM, Ritter O, et al. Endothelin-1-stimulated InsP<sub>3</sub>-induced Ca<sup>2+</sup> release is a nexus for hypertrophic signaling in cardiac myocytes. Mol Cell 2009; 33:472-82.
17. Li X, Zima AV, Sheikh F, Blatter LA, Chen J. Endothelin-1-induced arrhythmogenic Ca<sup>2+</sup> signaling is abolished in atrial myocytes of inositol-1,4,5-trisphosphate receptor (IP3R) type-2 deficient mice. Circ Res 2005; 96:1274-81.
18. Luo D, Yang D, Lan X, Li K, Li X, Chen J, et al. Nuclear Ca<sup>2+</sup> sparks and waves mediated by inositol 1,4,5-trisphosphate receptors in neonatal rat cardiac myocytes. Cell Calcium 2008; 43:165-74.
19. Lau DL, Guo J, Lam YC, Wang G, Wei S, Xiao RP, Hui JQ. Role of inositol-1,4,5-trisphosphate receptors in alpha-adrenergic receptor-induced cardiac myocyte hypertrophy. Acta Pharmacol Sin 2006; 27:985-908.
20. Mackenzie L, Bloom MD, Lane M, Berridge MJ, Thiering J, Holmes A, et al. The role of inositol 1,4,5-trisphosphate receptors in Ca<sup>2+</sup> signaling and the generation of arrhythmias in rat atrial myocytes. J Physiol 2002; 541,395-409.
21. Proven A, Roderick HL, Conway SJ, Berridge MJ, Horton JK, Capper SJ, Bootman MD. Inositol 1,4,5-trisphosphate receptors in heart failure. Trend Pharmacol Sci 2006; 27:895-900.
22. Zima AV, Blatter LA. Inositol-1,4,5-trisphosphate-dependent Ca<sup>2+</sup> signaling in cat atrial excitation-contraction coupling and arrhythmias. J Physiol 2004; 555:607-15.
23. Balke CW, Shonofsky SR. Alterations in calcium handling in cardiac hypertrophy and heart failure. Cardiovasc Res 1998; 37:290-9.
24. Carvalho BM, Bassani RA, Franchini KG, Bassani JW. Enhanced calcium mobilization in rat ventricular myocytes during the onset of pressure overload-induced hypertrophy. Am J Physiol Heart Circ Physiol 2006.
25. Kahan T, Bergfeldt L. Left ventricular hypertrophy in hypertension: its arrhythmogenic potential. Heart 2006; 51:96-104.
26. Zolk O, Quattet K, Seilund U, El-Armouche A, Koster M, Kainer MK, Piasek B. Endothelin-1 enhances nuclear Ca<sup>2+</sup> transients in atrial myocytes through InsP3<sub>3</sub>-dependent Ca<sup>2+</sup> release from perinuclear Ca<sup>2+</sup> stores. J Cell Sci 2008; 121:186-95.
27. Bootman MD, Higazi DR, Coombers S, Roderick HL. Calcium signaling during excitation-contraction coupling in mammalian atrial myocytes. J Cell Sci 2006; 119:3915-25.
28. Iyer RS, Singh G, Rebellio S, Roy S, Bhat R, Vidyasagar D, Gilati A. Changes in the concentraion of endothelin-1 during development of hypertenive rats. Pharmacology 1995; 51:96-104.
29. Zolk O, Quattet K, Seilund U, El-Armouche A, Eschenbagen T, Bohm M. Activation of the cardiac endothelin system in left ventricular hypertrophy before onset of heart failure in TG(mREN2)27 rats. Cardiovasc Res 2002; 53:563-71.
30. Woodcock EA, Grubb DR, Filtz TM, Marasco S, Luo J, McLeod-Dryden TJ, et al. Selective activation of the “b” splice variant of phospholipase Cbeta1 in chronically dilated human and mouse atria. J Mol Cell Cardiol 2009.
31. Clarke MC, Figg N, Maguire JI, Davenport AP, Goddard M, Littlewood TD, Bennett MR. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med 2006; 12:1075-80.
32. Kasri NN, Holmes AM, Balnynck G, Parry JB, Bootman MD, Riedorf K, et al. Regulation of InsP<sub>3</sub> receptor activity by neuronal Ca<sup>2+</sup> binding proteins. EMBO J 2004; 23:312-21.